Premium
Evaluation of efficacy and safety of dexamethasone intravitreal implants between vitrectomized and non‐vitrectomized eyes in a real‐life study
Author(s) -
Rezkallah A.,
Malcles A.,
Dot C.,
Voirin N.,
Agard E.,
Vie A.L.,
Denis P.,
Kodjikian L.
Publication year - 2017
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2017.01115
Subject(s) - vitrectomy , pars plana , medicine , ophthalmology , dexamethasone , visual acuity , implant , retrospective cohort study , surgery
Purpose To compare the efficacy and safety of dexamethasone intravitreal implant (Ozurdex) between vitrectomized and non‐vitrectomized eyes in real‐life conditions and to evaluate the change in intravitreal DEX ‐implant efficacy before and after pars‐plana vitrectomy ( PPV ) in patients vitrectomized during follow‐up Methods This was a bicentric, retrospective, observational study. Four hundred and one eyes in 361 patients were enrolled between October 2010 and February 2015. Sixty‐seven eyes were vitrectomized at baseline, 301 had no vitrectomy at the last visit. Fifteen eyes were vitrectomized during follow‐up and had at least one DEX ‐implant intravitreal injection before and after PPV . Eighteen eyes vitrectomized during the follow‐up were excluded because these eyes did not have at least one intravitreal injection of DEX ‐Implant after pars‐plana vitrectomy. Three hundred eighty‐three eyes in 343 patients were studied. We evaluated the efficacy and safety of OzurdexÓ between vitrectomized and non‐vitrectomized eyes and before and after PPV in patients vitrectomized during follow‐up. Main outcome measures included changes in best‐corrected visual acuity, central macular thickness and incidence of adverse effects. Results Variations of BCVA and CMT were not significantly different neither between non‐vitrectomized eyes and baseline‐vitrectomized eyes nor before and after PPV in patients vitrectomized during follow‐up. The IOP profile was the same between non‐vitrectomized eyes versus baseline‐vitrectomized eyes and before versus after PPV in patients vitrectomized during the follow‐up. Conclusions This large cohort shows that vitrectomy seems not to influence the efficacy and safety profile of DEX implant regardless of the indication.